Beam Therapeutics reports pipeline progress, ~$1B cash, and outlines milestones for 2023-2024

Beam Therapeutics Inc.

Estimated $1.0B cash, cash equivalents, and marketable securities as of Dec 31, 2022; cash runway expected into 2025.
BEAM-101 (SCD): BEACON trial sentinel cohort enrollment completion and expansion cohort initiation expected in 2023; data from multiple patients in 2024.
BEAM-201 (T-ALL/T-LL): FDA IND clearance; first patient dosing expected by mid-2023 in Phase 1/2 trial.
BEAM-301 (GSDIa) regulatory submission planned by late 2023/early 2024; BEAM-302 (AATD) submission planned early 2024.
North Carolina manufacturing facility expected to initiate GMP operations in late 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.